Il-18 variant polypeptides

Abstract

Provided are interleukin 18 (IL-18) variant polypeptides that comprise mutation(s) at one or more of G3, E6, D54, and N91, wherein amino acid positions are relative to a wild-type human IL-18 set forth in SEQ ID NO: 1. Also provided are IL-18 variant polypeptide comprising (such as further comprising) at least one mutation at a residue selected from the group consisting of: C38, C68, C76, D98, S117, and C127, wherein the amino acid position is relative to a wild-type human IL-18 set forth in SEQ ID NO: 1. Also provided are IL-18 variant polypeptides bind IL-18Rα and exhibit substantially reduced binding to IL-18BP relative to the wild-type IL-18. Also provided are IL-18 variant polypeptides that exhibit increased binding IL-18Rα relative to the wild-type IL-18 and substantially reduced binding to IL-18BP relative to the wild-type IL-18. Also provided are related nucleic acids, vectors, host cells, methods of producing IL-18 variant polypeptides, pharmaceutical compositions comprising IL-18 variant polypeptides, and uses of such pharmaceutical compositions.

Dependencies are inferred from the claim text.